Open-Label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donepezil in Patients With Alzheimer Disease

Open Access
Publisher Website
Google Scholar
Abstract
TO DATE, the most successful agents developed for the treatment of Alzheimer disease (AD) are the acetylcholinesterase inhibitors,1-4 of which donepezil hydrochloride is currently the most widely used. The clinical benefits of donepezil treatment have been demonstrated in 4 clinical trials,3,5-7 in which significant improvements in cognition and global function have been observed in studies of up to 24 weeks' duration. However, the optimal time for continuing donepezil treatment beyond 24 weeks to maintain benefits remains an important clinical question.